Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering ...

Analysts at Truist Securities called the mid-stage data a "mixed bag," also flagging gastrointestinal adverse events. However ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) said on Thursday that it presented results from its Phase 2 DAZALS study of ...

Corcept Therapeutics' dazucorilant failed the primary ALS trial goal but showed improved survival outcomes and a safe profile ...

Although DAZALS did not meet its primary endpoint, patient survival significantly improved. At week 24 of the study, no ...

We recently published a list of These 10 Stocks Already Sank in June. In this article, we are going to take a look at where ...

US commercial-stage drugmaker Corcept Therapeutics (Nasdaq: CORT) has presented results from its DAZALS study of dazucorilant ...

We are working with regulatory authorities to determine the optimal path for advancing dazucorilant,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer. “We would like to thank ...

H.C. Wainwright analysts on Tuesday maintained their $145 price target and Buy rating for Corcept Therapeutics Incorporated ...

Corcept Therapeutics CORT has outperformed the market over the past 5 years by 26.38% on an annualized basis producing an ...

We want to thank all the patients and investigators who participated in this trial,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer. “These data also illustrate the benefits of ...